Biomerica Inc. (NASDAQ: BMRA) today announced it has commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test (a finger prick blood test with results in 10 minutes, that can be performed by trained professionals anywhere, e.g. Evaluation test kits have been requested by Ministries of Health in multiple countries through the Company’s distribution partners who are working with their government agencies to assess the tests and forecast demand. This disposable point-of-care serology test is different than the current polymerase chain reaction (PCR) tests in that initial studies indicate that serology tests can identify if someone has been exposed to the COVID-19 virus, and can further detect if a person was recently infected with the disease even if they have never shown or are no longer showing symptoms.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) * Imara Inc (NASDAQ: IMRA)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) * 89bio Inc (NASDAQ: ETNB) * AC Immune SA (NASDAQ: ACIU) * Acasti Pharma Inc (NASDAQ: ACST) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adamis Pharmaceuticals Corp (NASDAQ: ADM) * Adial Pharmaceuticals Inc (NASDAQ: ADIL) * ADMA Biologics Inc (NASDAQ: ADMA) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Agenus Inc (NASDAQ: AGEN) * Agios Pharmaceuticals Inc (NASDAQ: AGIO) * Aikido Pharma Inc (NASDAQ: AIKI) * Akorn, Inc. (NASDAQ: AKRX) * Alkermes Plc (NASDAQ: ALKS) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) * Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) * AngioDynamics, Inc. (NASDAQ: ANGO) * Anika Therapeutics Inc (NASDAQ: ANIK) * Anixa Biosciences Inc (NASDAQ: ANIX) * Antares Pharma Inc (NASDAQ: ATRS) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * Aptinyx Inc (NASDAQ: APTX) * Arca Biopharma Inc (NASDAQ: ABIO) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Aridis Pharmaceuticals Inc (NASDAQ: ARDS) * Assertio Therapeutics Inc (NASDAQ: ASRT) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Athenex Inc (NASDAQ: ATNX) * Avanos Medical Inc (NYSE: AVNS) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Bausch Health Companies Inc (NYSE: BHC) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) * BIO-TECHNE Corp (NASDAQ: TECH) * BioCardia Inc (NASDAQ: BCDA) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) * BIOFRONTERA AG/ADR (NASDAQ: BFRA) * BIOLASE Inc (NASDAQ: BIOL) * BIOLINERX LTD/S ADR (NASDAQ: BLRX) * BioNano Genomics Inc (NASDAQ: BNGO) * BioSig Technologies Inc (NASDAQ: BSGM) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) * BioTelemetry Inc (NASDAQ: BEAT) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Boston Scientific Corporation (NYSE: BSX) * BridgeBio Pharma Inc (NASDAQ: BBIO) * Cabaletta Bio Inc (NASDAQ: CABA) * Caladrius Biosciences Inc (NASDAQ: CLBS) * Cara Therapeutics Inc (NASDAQ: CARA) * CareDx Inc (NASDAQ: CDNA) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) * Catalent Inc (NYSE: CTLT) * Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Cellectis SA (NASDAQ: CLLS) * CELYAD SA/ADR (NASDAQ: CYAD) * Chiasma Inc (NASDAQ: CHMA) * Chimerix Inc (NASDAQ: CMRX) * Coherus Biosciences Inc (NASDAQ: CHRS) * DelMar Pharmaceuticals Inc (NASDAQ: DMPI) * Dyadic International, Inc. (NASDAQ: DYAI) * Edesa Biotech Inc (NASDAQ: EDSA) * Elanco Animal Health Inc (NYSE: ELAN) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Enzo Biochem, Inc. (NYSE: ENZ) * Erytech Pharma SA (NASDAQ: ERYP) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Evogene Ltd (NASDAQ: EVGN) * EXACT Sciences Corporation (NASDAQ: EXAS) * Exicure Inc (NASDAQ: XCUR) * Eyenovia Inc (NASDAQ: EYEN) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * FibroGen Inc (NASDAQ: FGEN) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Flexion Therapeutics Inc (NASDAQ: FLXN) * Galera Therapeutics Inc (NASDAQ: GRTX) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) * Genocea Biosciences Inc (NASDAQ: GNCA) * Glaukos Corp (NYSE: GKOS) * Global Cord Blood Corp (NYSE: CO) * Global Blood Therapeutics Inc (NASDAQ: GBT) * GlycoMimetics Inc (NASDAQ: GLYC) * Gossamer Bio Inc (NASDAQ: GOSS) * Gritstone Oncology Inc (NASDAQ: GRTS) * Haemonetics Corporation (NYSE: HAE) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Harvard Bioscience, Inc. (NASDAQ: HBIO) * Helius Medical Technologies Inc (NASDAQ: HSDT) * Hepion Pharmaceuticals Inc (NASDAQ: HEPA) * Hologic, Inc. (NASDAQ: HOLX) * Illumina, Inc. (NASDAQ: ILMN) * Immunovant Inc (NASDAQ: IMVT) * Incyte Corporation (NASDAQ: INCY) * Innovate Biopharmaceuticals Inc (NASDAQ: INNT) * Innoviva Inc (NASDAQ: INVA) * Insmed Incorporated (NASDAQ: INSM) * Inspire Medical Systems Inc (NYSE: INSP) * Intec Pharma Ltd (NASDAQ: NTEC) * Integra Lifesciences Holdings Corp (NASDAQ: IART * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Iterum Therapeutics PLC (NASDAQ: ITRM) * Jaguar Health Inc (NASDAQ: JAGX) * Kalvista Pharmaceuticals Inc (NASDAQ: KALV) * KemPharm Inc (NASDAQ: KMPH) * Kezar Life Sciences Inc (NASDAQ: KZR) * Kindred Biosciences Inc (NASDAQ: KIN) * Kura Oncology Inc (NASDAQ: KURA) * Laboratory Corp. of America Holdings (NYSE: LH) * Lantheus Holdings Inc (NASDAQ: LNTH) * Liminal BioSciences Inc (NASDAQ: LMNL) * Lipocine Inc (NASDAQ: LPCN) * MacroGenics Inc (NASDAQ: MGNX) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * Mallinckrodt PLC (NYSE: MNK) * Medigus Ltd. (NASDAQ: MDGS) * Medtronic PLC (NYSE: MDT) * MEI Pharma Inc (NASDAQ: MEIP) * MeiraGTx Holdings PLC (NASDAQ: MGTX) * Menlo Therapeutics Inc (NASDAQ: MNLO) * MEREO BIOPHARMA/ADR (NASDAQ: MREO) * Merrimack Pharmaceuticals Inc (NASDAQ: MACK) * Merus NV (NASDAQ: MRUS) * Midatech Pharma PLC-ADR (NASDAQ: MTP) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) * Miragen Therapeutics Inc (NASDAQ: MGEN) * Morphosys Ag (NASDAQ: MOR) * MYOS Corporation common stock (NASDAQ: MYOS) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Natera Inc (NASDAQ: NTRA) * Natus Medical Inc (NASDAQ: NTUS) * Neos Therapeutics Inc (NASDAQ: NEOS) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO) * Neuronetics Inc (NASDAQ: STIM) * NewLink Genetics Corp (NASDAQ: NLNK) * Novus Therapeutics Inc (NASDAQ: NVUS) * NuVasive, Inc. (NASDAQ: NUVA) * Obalon Therapeutics Inc (NASDAQ: OBLN) * OptiNose Inc (NASDAQ: OPTN) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Organovo Holdings Inc (NASDAQ: ONVO) * Orthofix Medical Inc (NASDAQ: OFIX) * Otonomy Inc (NASDAQ: OTIC) * Oxford Immunotec Global PLC (NASDAQ: OXFD) * Outlook Therapeutics Inc (NASDAQ: OTLK) * Pacific Biosciences of California (NASDAQ: PACB) * Pacira Biosciences Inc (NASDAQ: PCRX) * Passage Bio Inc (NASDAQ: PASG) * PDS Biotechnology Corp (NASDAQ: PDSB) * PLx Pharma Inc (NASDAQ: PLXP) * Precipio Inc (NASDAQ: PRPO) * Predictive Oncology Inc (NASDAQ: POAI) * Psychemedics Corp. (NASDAQ: PMD) * Quest Diagnostics Inc (NYSE: DGX) * Rapt Therapeutics Inc (NASDAQ: RAPT) * REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) * Regenxbio Inc (NASDAQ: RGNX) * resTORbio, Inc. (NASDAQ: TORC) * Retrophin Inc (NASDAQ: RTRX) * Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Salarius Pharmaceuticals Inc NASDAQ: SLRX * SCYNEXIS Inc (NASDAQ: SCYX) * Seneca Biopharma Inc (NASDAQ: SNCA) * Shockwave Medical Inc (NASDAQ: SWAV) * SI-Bone Inc (NASDAQ: SIBN) * Sierra Oncology Inc (NASDAQ: SRRA) * Silk Road Medical Inc (NASDAQ: SILK) * Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) * Stealth BioTherapeutics Corp (NASDAQ: MITO) * Stemline Therapeutics Inc (NASDAQ: STML) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * SurModics, Inc. (NASDAQ: SRDX) * Takeda Pharmaceutical Co Ltd (NYSE: TAK) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * TELA Bio Inc (NASDAQ: TELA) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TherapeuticsMD Inc (NASDAQ: TXMD) * Therapix Biosciences Ltd - ADR (NASDAQ: TRPX) * Theratechnologies Inc (NASDAQ: THTX) * Titan Medical Inc. (NASDAQ: TMDI) * Trevena Inc (NASDAQ: TRVN) * Trevi Therapeutics Inc (NASDAQ: TRVI) * Tricida Inc (NASDAQ: TCDA) * Trinity Biotech plc (NASDAQ: TRIB) * TrovaGene Inc (NASDAQ: TROV) * Twist Bioscience Corp (NASDAQ: TWST) * Urogen Pharma Ltd (NASDAQ: URGN) * Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) * Vascular Biogenics Ltd (NASDAQ: VBLT) * Veracyte Inc (NASDAQ: VCYT) * Vericel Corp (NASDAQ: VCEL) * VERONA PHARMA P/S ADR (NASDAQ: VRNA) * Viveve Medical Inc (NASDAQ: VIVE) * VIVUS, Inc. (NASDAQ: VVUS) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Xenetic Biosciences Inc (NASDAQ: XBIO) * Xenon Pharmaceuticals Inc (NASDAQ: XENE) * Xeris Pharmaceuticals Inc (NASDAQ: XERS) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) * Zimmer Biomet Holdings Inc (NYSE: ZBH) * Zoetis Inc (NYSE: ZTS) * Zogenix, Inc. (NASDAQ: ZGNX)See Also: 8 Biotechs With Coronavirus Vaccines In DevelopmentStocks In Focus Moleculin To Test Candidates For Coronavirus Canada's WPD Pharma said its licensing partner Moleculin Biotech Inc (NASDAQ: MBRX) has entered into an agreement with a leading government funded research facility in the U.S. to conduct research on its patented portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus.In pre-market trading Thursday, Moleculin stock was rallying 134.49% to $1.10.Roche's Genentech To Evaluate Drug For COVID-19 Pneumonia Roche Holdings AG Basel ADR (OTC: RHHBY)'s Genentech unit said it is working with the BARDA to evaluate the safety and efficacy of Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.The company said the global study is expected to begin enrolling as soon as possible in early April with 330 patients.Novartis's Zolgensma Gets Japanese Regulatory Approval Novartis AG (NYSE: NVS) said the Japanese Ministry of Health, Labor and Welfare approved its gene therapy Zolgensma for treating spinal muscular atrophy in patients aged under two.Separately, the company said it is voluntarily recalling 100mg sandimmune and neural prescription drug blister packages due to the failure to meet child-resistant packaging requirement. If it is consumed by children, it exposes them to toxicity risk, the company said.Separately, the company announced publication in the New England Journal of Medicine results of three pivotal Phase III clinical trials for inclisiran, a siRNA investigational agent for hyperlipidemia in adults, which showed achievement of primary endpoints and safety.J&J Submits NDA For Multiple Sclerosis Drug Johnson & Johnson (NYSE: JNJ)'s Janssen unit announced the submission of an NDA, seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis.Bio-Rad's Real-Time qPCR Products Used by Labs For COVID-10 Screening Bio-Rad Laboratories, Inc. (NYSE: BIO) said its Real-Time qPCR products are being used by testing laboratories globally to screen for COVID-19.Dyadic's Platform to be Used By Israeli Research Institution to Develop COVID-19 Treatment Participating in the 32nd Annual ROTH Conference, which was held virtually, Dyadic said the Israeli Institute For Biologic Research will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both a rVaccine candidate and monoclonal antibodies for COVID-19 treatmentIn pre-market trading, the stock was adding 25.19% to $3.23.Qiagen's COVID-19 Test Gets CE Mark In Europe Qiagen NV (NYSE: QGEN) said it has obtained CE marking for its newly-developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic to detect SARS-CoV-2.Pfizer's Eczema Drug Aces Latestage Study Pfizer Inc. (NYSE: PFE) said the Phase 3 JADE COMPARE study that evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 inhibitor, in adults with moderate to severe atopic dermatitis who were also on background topical therapy, met its co-primary efficacy endpoints.View more earnings on IBB"These data, along with other results from other pivotal trials, MONO-1 and MONO-2, will support filings with regulatory bodies, starting with the US Food and Drug Administration (FDA) planned for later this year," the company said.Dicerna's Genetic Disorder Drug Gets Orphan Drug Designation Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) said the FDA granted orphan drug designation to its DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency - a genetic disorder that can cause lung and liver disease.In pre-market trading, the stock was adding 4.09% to $14.Earnings Capricor Therapeutics Inc's (NASDAQ: CAPR) fourth-quarter net loss narrowed from $1.05 per share to 34 cents per share, in line with the consensus. As of Dec. 31, 2019, cash, cash equivalents and marketable securities totaled about $9.9 million, compared to approximately $7.3 million on Dec. 31, 2018.In pre-market trading, the stock was slipping 5.36% to $1.18.Acer Therapeutics Inc (NASDAQ: ACER) said its fourth-quarter loss per share narrowed from 85 cents to 51 cents, while analyst estimated a narrower loss of 48 cents per share. Cash and cash equivalents were $12.1 million as of Dec. 31, 2019, compared to $41.7 million as of Dec. 31, 2018. The company said it believes its cash position will suffice to fund operations till the end of 2020, excluding support for Edsivo development and precommercial activities, and the planned osanetant clinical trial.Separately, the company said the Office of New Drugs of the FDA has denied its appeal of the Complete Response Letter for EDSIVO NDA.In pre-market trading, the stock was slipping 5.94% to $1.90.On The Radar Earnings Vascular Biogenics Ltd (before the market open) Zai Lab Ltd (NASDAQ: ZLAB) (before the market open) Hookipa Pharma Inc (NASDAQ: HOOK) (before the market open) BIOLASE Inc (NASDAQ: BIOL) (before the market open) Auris Medical Holding Ltd (NASDAQ: EARS) (after the close) Curis, Inc. (NASDAQ: CRIS) (after the close) Viveve Medical Inc (NASDAQ: VIVE) (after the close)See more from Benzinga * 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades * The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Biomerica Inc. (NASDAQ: BMRA) (the “Company” or “Biomerica”) announced today that the Company completed a private placement of $2 million of convertible preferred stock with Palm Global Small Cap Master Fund LP ("Palm"). The preferred shares are initially convertible into shares of the Company's common stock at a price of $3.50 per share. This represents a premium to the market price of the Company’s common stock at the time of closing.

New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. Biomerica also announced it is now filling and has shipped commercial orders of its previously announced version of the product to Company distributors who are supplying customers that include NATO, and government agencies in Germany, Switzerland and the Netherlands. IRVINE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it has received a CE mark and launched a new high-volume production version of its COVID-19 IgG/IgM Rapid Test (a finger prick blood test with results in 10 minutes, that can be performed by trained professionals anywhere) being sold in countries outside the US.

Companies In The News Are: NEPT, BMRA, LK, WBA

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...

Biomerica, Inc. (BMRA) today reported net sales of $3,967,712 for the nine months ending February 29, 2020, compared to $4,034,822 for the period ended February 28, 2019. For the nine months ended February 29, 2020, the Company reported a net loss of $1,852,482 compared to net loss of $1,607,730 for the nine months in the previous fiscal year. Since the Company’s third quarter ended February 29, 2020, the above results do not include any revenues or expenses associated with the Company announcements of March 17, 2020, and April 2, 2020 relating to the Company’s SARS CoV-2 (COVID-19) serology IgG/IgM rapid antibody test and its ELISA serology IgG/IgM/IgA high-volume open system lab scale test.

Biomerica, Inc. (NASDAQ:BMRA) shareholders might be concerned after seeing the share price drop 16% in the last month...

Biomerica, Inc.'s (NASDAQ:BMRA): Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets...

Biomerica Inc. (NASDAQ: BMRA) today announced it has signed two separate definitive license agreements with Mount Sinai’s Icahn School of Medicine in New York to license technologies pertaining to a laboratory version serological test for SARS-CoV-2 (“COVID-19”) virus infection which have been developed at Mount Sinai. This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States. Biomerica has extensive serological test development, scale-up and manufacturing capabilities and expertise.

In the current session, Biomerica Inc. (NASDAQ: BMRA) is trading at $7.64, after a 16.6% spike. Over the past month, the stock increased by 2.41%, and in the past year, by 222.36%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently trading lower from its 52 week high by 67.34%.The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Biomerica has a lower P/E than the aggregate P/E of 4.41 of the diagnostics & research industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 17) * Abeona Therapeutics Inc (NASDAQ: ABEO) * AC Immune SA (NASDAQ: ACIU) * Acasti Pharma Inc (NASDAQ: ACST) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Acorda Therapeutics Inc (NASDAQ: ACOR) * Adamis Pharmaceuticals Corp (NASDAQ: ADM) * ADDEX THERAPEUT/ADR (NASDAQ: ADXN) * ADMA Biologics Inc (NASDAQ: ADMA) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * Agenus Inc (NASDAQ: AGEN) * Aimmune Therapeutics Inc (NASDAQ: AIMT) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alkermes Plc (NASDAQ: ALKS) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Alpine Immune Sciences Inc (NASDAQ: ALPN) * AngioDynamics, Inc. (NASDAQ: ANGO) * Anika Therapeutics Inc (NASDAQ: ANIK) * Antares Pharma Inc (NASDAQ: ATRS) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * Applied Genetic Technologies Corp (NASDAQ: AGTC) * Aptinyx Inc (NASDAQ: APTX) * Aridis Pharmaceuticals Inc (NASDAQ: ARDS) * Artelo Biosciences Inc (NASDAQ: ARTL) * Assertio Therapeutics Inc (NASDAQ: ASRT) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Athenex Inc (NASDAQ: ATNX) * Avrobio Inc (NASDAQ: AVRO) * Axonics Modulation Technologies Inc (NASDAQ: AXNX * Bio-Path Holdings Inc (NASDAQ: BPTH) * Biocept Inc (NASDAQ: BIOC) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) * BIOFRONTERA AG/ADR (NASDAQ: BFRA) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * BIOLASE Inc (NASDAQ: BIOL) * Biomerica, Inc. (NASDAQ: BMRA) * BioTelemetry Inc (NASDAQ: BEAT) * bluebird bio Inc (NASDAQ: BLUE) * BridgeBio Pharma Inc (NASDAQ: BBIO) * CareDx Inc (NASDAQ: CDNA) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) * Catalent Inc (NYSE: CTLT) * Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) * Celcuity Inc (NASDAQ: CELC) * Cerus Corporation (NASDAQ: CERS) * Chiasma Inc (NASDAQ: CHMA) * Coherus Biosciences Inc (NASDAQ: CHRS) * Conatus Pharmaceuticals Inc (NASDAQ: CNAT) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) * DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) * Dynavax Technologies Corporation (NASDAQ: DVAX) * Edwards Lifesciences Corp (NYSE: EW) * Enanta Pharmaceuticals Inc (NASDAQ: ENTA) * Enzo Biochem, Inc. (NYSE: ENZ) * Erytech Pharma SA (NASDAQ: ERYP) * Evogene Ltd (NASDAQ: EVGN) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * Exelixis, Inc. (NASDAQ: EXEL) * Flexion Therapeutics Inc (NASDAQ: FLXN * G1 Therapeutics Inc (NASDAQ: GTHX) * Galectin Therapeutics Inc. Common Stock (NASDAQ: GALT) * Galera Therapeutics Inc (NASDAQ: GRTX) * Glaukos Corp (NYSE: GKOS) * Gossamer Bio Inc (NASDAQ: GOSS) * Guardant Health Inc (NASDAQ: GH) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) * Haemonetics Corporation (NYSE: HAE) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Hologic, Inc. (NASDAQ: HOLX) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Ideaya Biosciences Inc (NASDAQ: IDYA) * Immunic Inc (NASDAQ: IMUX) * IMMURON LTD/S ADR (NASDAQ: IMRN) * Innoviva Inc (NASDAQ: INVA) * Insmed Incorporated (NASDAQ: INSM) * Inspire Medical Systems Inc (NYSE: INSP) * Intec Pharma Ltd (NASDAQ: NTEC) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Kindred Biosciences Inc (NASDAQ: KIN) * Kura Oncology Inc (NASDAQ: KURA) * Inspire Medical Systems Inc (NYSE: INSP) * Laboratory Corp. of America Holdings (NYSE: LH) * Lantheus Holdings Inc (NASDAQ: LNTH) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * Medigus Ltd. (NASDAQ: MDGS) * MeiraGTx Holdings PLC (NASDAQ: MGTX) * Merrimack Pharmaceuticals Inc (NASDAQ: MACK) * Mesoblast limited (NASDAQ: MESO) * Midatech Pharma PLC-ADR (NASDAQ: MTP) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) * Miragen Therapeutics Inc (NASDAQ: MGEN) * Monopar Therapeutics Inc (NASDAQ: MNPR) * Morphic Holding Inc (NASDAQ: MORF) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Natus Medical Inc (NASDAQ: NTUS) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO) * Neuronetics Inc (NASDAQ: STIM) * NuVasive, Inc. (NASDAQ: NUVA) * OncoSec Medical Inc (NASDAQ: ONCS) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Organovo Holdings Inc (NASDAQ: ONVO) * Orthofix Medical Inc (NASDAQ: OFIX) * Pacira Biosciences Inc (NASDAQ: PCRX) * PLx Pharma Inc (NASDAQ: PLXP) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * PRA Health Sciences Inc (NASDAQ: PRAH) * Precigen Inc (NASDAQ: PGEN) * Precipio Inc (NASDAQ: PRPO) * Precision BioSciences Inc (NASDAQ: DTIL) * Predictive Oncology Inc (NASDAQ: POAI) * Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) * PTC Therapeutics, Inc. (NASDAQ: PTCT) * Puma Biotechnology Inc (NASDAQ: PBYI) * Quest Diagnostics Inc (NYSE: DGX) * Retrophin Inc (NASDAQ: RTRX) * Revolution Medicines Inc (NASDAQ: RVMD) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * Rubius Therapeutics Inc (NASDAQ: RUBY) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Sesen Bio Inc (NASDAQ: SESN) * Shockwave Medical Inc (NASDAQ: SWAV) * SI-Bone Inc (NASDAQ: SIBN) * Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) * T2 Biosystems Inc (NASDAQ: TTOO) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * TELA Bio Inc (NASDAQ: TELA) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TherapeuticsMD Inc (NASDAQ: TXMD) * Titan Medical Inc. (NASDAQ: TMDI) * TrovaGene Inc (NASDAQ: TROV) * Twist Bioscience Corp (NASDAQ: TWST) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) * Urogen Pharma Ltd (NASDAQ: URGN) * Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) * Varian Medical Systems, Inc. (NYSE: VAR) * Vericel Corp (NASDAQ: VCEL) * Viking Therapeutics Inc (NASDAQ: VKTX) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Xencor Inc (NASDAQ: XNCR) * ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) * Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)See Also: 8 Biotechs With Coronavirus Vaccines In DevelopmentStocks In Focus Vaxart, Emergent Join Hands For Oral COVID-19 Vaccine, Clinical Trials to Begin In 2020 Vaxart Inc (NASDAQ: VXRT) said it has entered into an agreement with Emergent Biosolutions Inc (NYSE: EBS), which will allow Emergent to deploy its molecule-to-market contract development and manufacturing services to develop and manufacture the former's oral vaccine candidate for COVID-19."We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign, and Emergent is a great partner to help in this endeavor," SAID Wouter Latoud, CEO of Vaxart.Vaxart expects Emergent to produce bulk cGMP vaccine to allow it to initiate Phase 1 study in the second hand of 2020.In pre-market trading Wednesday, Vaxart shares were rallying 23.32% to $2.38.IMV Jumps Into The Fray For COVID-19 Vaccine Imv Inc (NASDAQ: IMV) said it's advancing the clinical development of a DPX-based vaccine candidate against COVID-19. It intends to develop its vaccine candidate DPX-COVID-19 in collaboration with lead investigators for the phase 1 clinical studyAbbVie, Allergan Agree To Divest Certain Assets To Consummate Proposed Merger AbbVie Inc (NYSE: ABBV) and Allergan plc (NYSE: AGN) said they have entered into a consent decree agreement with the FTC staff regarding the former acquiring the latter. Under the agreement, the companies agreed to divest brazikumab, an investigational autoimmune disorder drug, to AstraZeneca plc (NYSE: AZN), and Zenpep, a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, as well as Viokace, another pancreatic enzyme preparation, both to NESTLE S A/S ADR (OTC: NSRGY).View more earnings on IBBThe companies expect the deal to close in May 2020, compared to the initial deadline of early 2020.In after-hours trading, shares of AbbVie slipped 1.47% to $71.95, while Allergan shares rose 1.84% to $175.Addex To Delay Parkinson's Disease Drug Registrational Study, Release of Q4 Results Addex has postponed the start of the registrational efficacy and safety study of dipraglurant to treat levodopa induced dyskinesia in patients with Parkinson's disease due to the COVID-19 pandemic. The company also announced delaying the release of its fourth quarter results till April 8.Biomerica Begins International Shipments of COVID-19 Rapid Test Biomerica said it has commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test - a finger prick test with results in 10 minutes - to countries outside of the U.S."Biomerica is positioned to begin filling large international orders of this disposable one-use tests within weeks, assuming international product shipping channels remain open and active," the company said. The company has also begun the application process with the FDA for Emergency Use Authorization for its COVID-19 test.Qiagen To Ramp Up Production If COVID-19 Testing Reagents By 7 Times Qiagen NV Qiagen NV (NYSE: QGEN) said it plans to dramatically ramp global production capacity of RNA extraction kits used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19.From its historical capacity of manufacturing RNA nucleic acid extraction reagents for 1.5 million patient tests on a monthly basis, Qiagen now plans to ramp production of reagents to support more than 6.5 million patient tests a month by the end of April 2020 and over 10 million patient tests a month by the end of June.Obalon To Halt Sale of Weight Loss System In California Due To COVID-19 Obalon Therapeutics Inc (NASDAQ: OBLN), which markets the first FDA-approved swallowable gas-filled intragastric balloon system for treating obesity, said it has temporarily suspended sale of the system at its existing retail treatment centers in San Diego and Orange County, California in the wake of the COVID-19 threat.Earnings Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) reported a narrowing of its fourth-quarter loss from $8.21 in 2018 to $1.76 in 2019. Cash and cash equivalents stood at $14.2 million as of Dec. 31, 2019, compared with $8 million at Dec. 31, 2018.The stock jumped 22.46% to 35 cents in after-hours trading.On The Radar Clinical Readouts Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) is due to present at the Annual Congress on Pulmonology & Respiratory Medicine, already-released Phase 2 data for Poziotinib in non-small cell lung cancer with exon 20 insertion mutation in EGFR or HER2.Earnings Brickell Biotech Inc (NASDAQ: BBI) (after the close) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close) Capricor Therapeutics Inc (NASDAQ: CAPR) (after the close) Turning Point Therapeutics Inc (NASDAQ: TPTX) (after the close) Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) (after the close)See more from Benzinga * 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades * The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

By Brian Marckx, CFA NASDAQ:BMRA READ THE FULL BMRA RESEARCH REPORT Both the top and bottom lines of Biomerica’s (NASDAQ:BMRA) income statement were largely flat through the first six months of fiscal 2020 (ending October 31, 2019) as compared to the year-earlier period. While 1H 2020 saw sales in both Europe (which accounts for ~26% of BMRA’s total revenue) and the U.S. (~8% of total) slide by

Biomerica, Inc. (BMRA) today reported net sales of $1,596,408 for the three months ended November 30, 2019, compared to $1,500,791 for the same period in the previous year, an increase of 6.4%. Biomerica announced a net loss for the three months ended November 30, 2019 of $485,260, or $0.05 per share, versus a net loss of $477,244, or $0.05 per share, in the previous fiscal year during the same quarter. The net loss for the six months ended November 30, 2019 was $991,556, or $0.10 per share, compared to net loss of $928,984, or $0.10 per share in the prior fiscal year.

A look at the shareholders of Biomerica, Inc. (NASDAQ:BMRA) can tell us which group is most powerful. Large companies...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

IRVINE, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) --  Biomerica Inc. (NASDAQ: BMRA) today announced that Houston Methodist (part of Texas Medical Center, the largest medical complex in the world) will start enrollment  for the clinical trial of its new InFoods® diagnostic-guided therapy (DGT) to alleviate Irritable Bowel Syndrome (IBS) symptoms. Houston Methodist will join Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, and the University of Michigan as primary enrollment centers for this study.

By M. Marin NASDAQ:BMRA READ THE FULL BMRA RESEARCH REPORT In response to the current global health crisis, Biomerica (NASDAQ:BMRA) has developed a high-volume rapid 10-minute point-of-care test for exposure to the COVID-19 virus. The test is easy to use and portable, which means that it can be used at point-of-contact locations at airports, schools, businesses and other high-traffic venues.

But the note by Citigroup analysts does not explain where these millions of serological tests are going to come from, so some skepticism is in order.

A Citigroup report argues that mass antibody testing can quickly locate millions of Americans with immunity to Covid-19. There are snags: Who will provide the tests, are they accurate, and does infection produce immunity?